Tag Archive for: CRS

Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial

/in

Major operational milestone achieved with interim data on track for summer 2026 11 June 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred. This follows the successful completion of […]

Read more

Poolbeg Pharma plc – pre-IND meeting with the FDA for POLB 001

/in

FDA feedback supports Poolbeg’s proposed development pathway for POLB 001, providing further clarity for ongoing partnering discussions 26 May 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the positive outcome of a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug […]

Read more

Poolbeg Pharma plc – POLB 001 poster to be presented at EHA 2026 Congress

/in

13 May 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it will present data on POLB 001 at the European Hematology Association Congress (“EHA”), taking place 11-14 June 2026 in Stockholm, Sweden. Read more…

Read more

Poolbeg Pharma plc – POLB 001 cancer immunotherapy-induced CRS patent granted in Canada

/in

Further strengthening of Poolbeg’s global intellectual property portfolio 11 May 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the Canadian […]

Read more

Poolbeg Pharma plc – Results for the year ended 31 December 2025

/in

28 April 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its audited results for the year ended 31 December 2025. Read more…

Read more
© Optimum Strategic Communications.